Mila, a leading AI research institute, has formed a partnership with Sorintellis, a company specialising in AI-powered decision support systems for pharmaceutical portfolio management and clinical trial planning. This collaboration aims to address major challenges in the innovative pharmaceutical industry through the application of artificial intelligence.
Emmanuel Piffo, founder and CEO of Sorintellis, emphasised the potential of AI to overcome challenges in clinical drug development and pharmaceutical portfolio management. He highlighted the partnership's role in fostering networking within the AI ecosystem to develop innovative solutions that can accelerate patient access to high-value therapeutic medicines while optimising commercial value.
The partnership seeks to create innovative solutions that streamline clinical drug development and increase pharmaceutical pipeline productivity. By combining Sorintellis' strategic pharmaceutical management services with Mila's academic expertise, the collaboration aims to drive impactful innovation for societal benefit.
Stéphane Létourneau, Executive Vice-President of Mila, expressed enthusiasm for welcoming Sorintellis to their community of partners, acknowledging the pivotal role of AI in drug discovery and clinical trials.
By leveraging their combined expertise, the collaboration aims to address the multi-faceted challenges of drug development, potentially leading to more efficient R&D processes, better risk mitigation, and ultimately, faster access to innovative therapies for patients.